🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm

RecruitingNAAges 18 Years - 80 YearsAllFudan University
NCT06634979 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The study investigated the efficacy and safety of a selective lymph node strategy (no lower mediastinal lymph node dissection for upper lobe tumors and no upper mediastinal lymph node dissection for lower lobe tumors) in patients with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter cT1N0M0 infiltrating NSCLC, aiming to more accurately assess the prognosis of the selective lymph node dissection strategy for nodes with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Volunteer to participate in a clinical study and be willing to follow and have the ability to complete all trial procedures; * Age 18-80 years at time of signing informed consent (including threshold); * ECOG score 0 or 1; * No previous surgery for lung cancer; * Intraoperative or postoperative pathologically confirmed non-small cell lung cancer; * Single pulmonary nodule with mixed ground glass on CT, or multiple pulmonary nodules but the main lesion is the above nodules; * The proportion of solid components of the nodule is between 0.5 and 1, and the total size of the nodule is less than or equal to 2 cm; * Patients with clinical stage T1N0M0 surgically resectable; * Primary treatment without radiotherapy or chemotherapy. Exclusion Criteria: * T1N0M0 with a clinical stage other than 0.5 \< CTR \< 1 and a diameter of ≤ 2 cm; * Inability to perform complete surgical resection; * cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer; * Previous surgery for lung cancer; * Patients who have received radiotherapy or chemotherapy for non-primary treatment.
💊

What it tests

  • Selective lymph node dissection
📍

Where

1 site
Fudan University Shanghai Cancer Center
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy